SCHEMBL1879660

SCHEMBL1879660

c1ccc(CN2CCC(N(CCc3ccccn3)Cc3ccc(CNCc4ccccn4)cc3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 5/20 0.51
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SIGMAR1 Q99720 1/20 0.46
▸ HTR5A P47898 1/20 0.44
▸ BCHE P06276 3/20 0.43
▸ ACHE P22303 3/20 0.43
▸ BACE1 P56817 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.42
▸ CTNNB1 P35222 1/20 0.41
▸ TCF7L2 Q9NQB0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29823344 1.00 CXCR4 (0.51) CXCR4KMT2AMEN1RAB9ASIGMAR1
SCHEMBL29823986 0.87 MEN1 (0.41) CXCR4KMT2AMEN1RAB9ASIGMAR1
SCHEMBL1872883 0.87 MEN1 (0.41) CXCR4KMT2AMEN1RAB9ASIGMAR1
SCHEMBL29823432 0.85 CXCR4 (0.49) CXCR4SIGMAR1BCHEACHEBACE1
SCHEMBL1877188 0.85 CXCR4 (0.49) CXCR4SIGMAR1BCHEACHEBACE1
SCHEMBL5790256 0.81 KMT2A (0.41) CXCR4KMT2AMEN1RAB9AKDM4E
SCHEMBL29823211 0.80 KMT2A (0.50) KMT2AMEN1RAB9AALDH1A1
SCHEMBL1873995 0.80 KMT2A (0.50) KMT2AMEN1RAB9AALDH1A1
SCHEMBL1877208 0.78 ALDH1A1 (0.43) CXCR4KMT2AMEN1SIGMAR1BCHE
SCHEMBL29823258 0.78 ALDH1A1 (0.43) CXCR4KMT2AMEN1SIGMAR1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371361-A1 Methods to mobilize progenitor/stem cells Genzyme Global S.à.r.l. (LU) 2011-10-05 — — EP claimed
US-7935692-B2 Methods to mobilize progenitor/stem cells GENZYME CORPORATION (US) 2011-05-03 — — US claimed
US-20100035941-A1 METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION GENZYME CORPORATION 2010-02-11 — — US claimed
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds ANORMED INC. (CA) 2006-11-23 — — US claimed
EP-1163238-B1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2006-05-31 — — EP claimed
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-25 — — US claimed
US-20250295698-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS ENSOMA INC (US) 2025-09-25 — — US disclosed
US-20250032549-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS ENSOMA INC (US) 2025-01-30 — — US disclosed
US-20240285831-A1 METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION KEEFER, Edward (US) 2024-08-29 — — US disclosed
US-20240189387-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS ENSOMA, INC. 2024-06-13 — — US disclosed
EP-3735412-B1 COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS EDIGENE BIOTECHNOLOGY INC (CN) 2024-02-21 — — EP disclosed
US-20230414565-A1 COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES ENSOMA, INC. 2023-12-28 — — US disclosed
US-20230330185-A1 METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO ENSOMA, INC. 2023-10-19 — — US disclosed
US-6987102-B2 Methods to mobilize progenitor/stem cells ANORMED, INC. (CA) 2006-01-17 — — US disclosed
US-20050043367-A1 Methods to mobilize progenitor/stem cells ANORMED CORPORATION (CA) 2005-02-24 — — US disclosed
WO-2005000333-A1 METHODS TO MOBILIZE PROGENITOR/STEM CELLS ANORMED INC. (CA) 2005-01-06 — — WO disclosed
US-6750348-B1 PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE ANORMED, INC. (CA) 2004-06-15 — — US disclosed
EP-1411918-A2 METHODS TO MOBILIZE PROGENITOR/STEM CELLS ANORMED INC. (CA) 2004-04-28 — — EP disclosed
US-20030130250-A1 Methods to mobilize progenitor/stem cells ANORMED, INC. (CA) 2003-07-10 — — US disclosed
WO-2003011277-A2 METHODS TO MOBILIZE PROGENITOR/STEM CELLS ANORMED INC. (CA) 2003-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 CXCR4 2/4885KMT2A 4150/4885MEN1 4013/4885
US-20240189387-A1 DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS CXCL12, MCL1, MYADM CXCR4 11/4885KMT2A 1317/4885MEN1 70/4885
US-20050043367-A1 Methods to mobilize progenitor/stem cells CXCL12, CXCR4, CXCR1 CXCR4 2/4885KMT2A 1572/4885MEN1 4770/4885
US-20230414565-A1 COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES MCL1, CXCL12, KIT CXCR4 20/4885KMT2A 1864/4885MEN1 667/4885
US-20100035941-A1 METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION CCR2, CXCR4, CXCR2 CXCR4 2/4885KMT2A 1732/4885MEN1 4046/4885
US-20230330185-A1 METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO CD44, MCL1, NFATC1 CXCR4 119/4885KMT2A 1142/4885MEN1 1621/4885
US-20250032549-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS CXCL12, CD44, CD47 CXCR4 7/4885KMT2A 1455/4885MEN1 1187/4885
US-20240285831-A1 METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION CXCR3, CXCL12, CXCR4 CXCR4 3/4885KMT2A 3729/4885MEN1 4348/4885
US-20030130250-A1 Methods to mobilize progenitor/stem cells CXCR4, CXCL12, CXCR2 CXCR4 1/4885KMT2A 1274/4885MEN1 3350/4885
US-20250295698-A1 DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS CXCL12, CSF3R, THPO CXCR4 12/4885KMT2A 1994/4885MEN1 185/4885
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 CXCR4 2/4885KMT2A 4002/4885MEN1 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback